Drug Study

Generic

Name

Brand

Name

Classifica

tion

Mechanism

of Action

Indicatio

n

Contraindic

ation

Side

Effects

How

Suppli

ed

Dosage

/

Freque

ncy

Nursing

Intervention

Omepraz

ole

Omepr

on

Proton

pump

inhibitor

Thought to

be a gastric

pump

inhibitor in

that it blocks

the final

step of acid

production

inhibiting

the H+

an/K+

ATPase

system at

Short

term

treatme

nt of

active

duodena

l ulcer.

Short

term (4-

8

weeeks)

treatme

nt of

Lactation.

Use as

maintenanc

e therapy

for

duodenal

ulcer

disease.

OTC use in

those who

have

trouble of

pain

Headac

he,

abdomi

nal

pain,

diarrhe

a, N&V,

URTI,

dizzines

s, rash.

IV

infusio

n

40mg

Once a

day

1.Consider

dosage

adjustment in

those with

impaired hepatic

function

especially when

used for

maintaining

clients with

erosive

esophagitis.

2.List reason for

123

the

secretory

surface of

the gastric

parietal cell.

Both basal

and

stimulated

acid

secretions

are

inhibited.

Serum

gastrin

levels are

increased

during the

first 1 to 2

weeks of

therapy and

erosive

esophagi

tis

diagnose

d by

endosco

py.

Maintain

healing

of

erosive

esophagi

tis.

Treatme

nt of

heartbur

n and

other

sympto

ms

swallowing

food, are

vomiting

blood, or

excreting

bloody or

black

stools.

therapy, triggers,

frequency,

characteristics of

S&S, other agents

trialed.

3.Record

abdominal

assessment,

radiographic/end

oscopic findings,

and H. pylori

result.

4.Administer one

hr before giving

meal.

5. Report any

changes in

urinary

elimination, pain,

discomfort, or

124

are

maintained

at such

levels during

the course

of therapy.

(Spratto

et.al.:2008:1

159)

associat

ed with

GERD.

persistent

diarrhea.

6. Avoid activities

that require

mental alertness

until drug effects

realized; may

cause dizziness.

7. For short term

use only, drug

inhibits total

gastric acid

secretion. Side

effects of

prolonged

therapy and

suppression of

acid secretion

alter bacterial

colonization and

125

lead to

hypoclorhydria

and

hypergastrenemi

a which may

cause an increase

risk for gastric

tumors.

Drug Study

Generic

Name

Bran

d

Nam

e

Classifica

tion

Mechanism

of Action

Indication Contraindic

ation

Side

Effects

How

Suppli

ed

Dosage

/

Freque

ncy

Nursing

Intervention

Piperacill

in

sodium

and

Zosy

n,

Pept

az

Antibiotic

,

Penicillin

A

combination

of

Piperacillin

(1)Appendi

citis

complicate

d by

Hypersensit

ivity to

penicillins,

cephalospor

Diarrhea,

constipat

ion, N&V,

dyspepsi

IV

infusio

n

4.5 gm

IV q 8

hours

1.For IV

administration

or infusion,

reconstitute

126

Tazobact

am

sodium

sodium and

Tazobactam

sodium, a

beta-

lactamase

inhibitor.

Tazobactam

inhibits

beta-

lactamases,

thus

ensuring

activity of

piperacillin

against

beta-

lactamase-

producing

microorganis

ms. Thus

rupture or

abscess

and

peritonitis

caused by

piperacillin

-resistant,

beta-

lactamase

producing

strains of

Escherichi

a coli,

Bacteroide

s fragillis.

(2)Commu

nity

Acquired

Pneumonia

of

ins, or beta-

lactamase

inhibitors.

a,

headach

e, rash,

rhinitis,

dyspnea,

abdomin

al pain.

the powder for

injection with 5

ml suitable

diluent/gram

piperacillin. IV

diluents that

can be used

include 0.9%

NaCl, sterile

water for

injection,

dextran 6% in

saline,D5W,KCl

40mEq,

bacteriostatic

saline/paraben

s,

bacteriostatic

water/parabens

, bacteriostatic

127

Tazobactam

broadens

the

antibiotic

spectrum or

piperacillin

to those

bacteria

normally

resistant to

it. (Spratto

et.al.:2008:1

269)

moderate

severity

caused by

piperacillin

-resistant,

beta-

lactamase

producing

strains of

Haemophil

us

influenzae.

(3)Moderat

e to severe

nosocomia

l

pneumonia

caused by

piperacillin

-resistant,

saline/benzyl

alcohol,bacteri

ostatic

water/benzyl

alcohol.

2.Note reasons

for therapy,

type, location,

characteristics

of S&S.

3. List any

sensitivity to

penicillins,

cephalosporins,

beta-lactamase

inhibitors, or

other allergens.

4. List drug

prescribed to

ensure none

128

beta-

lactamase

producing

strains of

Acinetobac

ter

baumanii.

(4)

Infections

caused by

piperacillin

-

susceptible

organisms

for which

piperacillin

is effective

may also

be treated

with this

interact

unfavorably.

Use of heparin

and oral

anticoagulants

may require

dosage

adjustments.

5. Monitor C&S,

lytes,

urinalysis,

hematologic,

coagulation

profile, renal,

LFTs; reduce

dosage with

renal

impairment.

6. Inform

family to report

129

combinatio

n.

any pain at

injection site,

fever/chills,

rash, diarrhea,

GI upset, lack

of response or

worsening of

condition.

Drug Study

Generic

Name

Bran

d

Nam

e

Classificat

ion

Mechanis

m of

Action

Indication Contraindica

tion

Side

Effects

How

Suppli

ed

Dosage/

Frequen

cy

Nursing

Intervention

clopidog

rel

winto

p

Anti-

platelet

drug

Inhibits

platelet

aggregati

Reduction

of MI,

stroke and

Lactation,

active

pathological

Appenda

ge

disorder

Tablet

s 75

mg

Clopidog

ral 75

mg i tab,

>Do not cofuse

with

antidepreesant

130

on by

inhibiting

binding of

adenosin

e

diphosph

ate (ADP)

to its

platelet

receptor

and

susbsequ

ent ADP

meditativ

e

activation

of

glycoprot

ein

GPII/IIa

ucercular

death in

patients

with

atheroscler

osis

documente

d by recent

stroke, MI

or

established

peripheral

arterial

disease

bleeding

such us

peptic ulcer

or

intracranial

hemorrhage

s,

headach

e, chest

pain, flu-

like

sympto

ms

PO,OD > Document

otheros dehoric

event or

established

peripheral

arterial disease

requiring

therapy.

> Asses for

active bleeding

as with ulcers or

intracranial

bleeding.

> list all drugs

prescribed/cons

umed esp. OTC.

> Consider 5

rights in giving

meds.

> Explain the

131

complex.

Effect on

receptors

is

irreversib

le thus

platelets

are

affected

for

remainde

r of their

lifespan.

(MIMS.co

m)

purpose of the

medication.

> obtain

baseline V/S.

> Document the

procedure.

132

Drug Study

Generic

Name

Brand

Name

Classificat

ion

Mechanis

m of

Action

Indicatio

n

Contraindica

tion

Side Effects How

Supplied

Dosage/

Frequen

cy

Nursing

Interventio

n

Acytylcyst

ien

Flulmu

cil

sachet

Mucolytic

s

Decrease

the

productio

n of

Acute

and

chronic

respirat

Contraindica

ted to

patients

having

Urticaria

bronchospa

sm, nausea,

vomiting.

100

mg

/200mg

sachet

200 mg

1 sachet

+ socc

h20

asses drug

expiration

date

>asses for

133

mucus at

respirator

y tracts

by

stimulatin

g the

productio

n of

glutathia

nce thus

decreasin

g the

viscosity

of

secretion

s.

ory tract

affection

s with

abundan

t mucus

secretio

ns.

asthma.

Patients with

history of

peptic ulcer.

Inhalatio

n

100mg/

ml

Syrup

100mg/5

ml x 150

ml

NGT bid drug

tolerance

characteri

zed

>obtain

baseline

v/s

>take the

drug with

meals

>advice

increase

fluid

intake

>consider

patients

safety

>evaluate

effectiven

ess of

134

drug

>chart

procedure

Drug Study

Generic

Name

Brand

Name

Classificat

ion

Mechanis

m of

Action

Indication Contraindica

tion

Side

Effects

How

Suppli

ed

Dosage/

Frequen

cy

Nursing

Interventio

n

Simvasta

tin

Vidast

at

Dyslipide

mic Agent

Reductio

n of low

density

lipprotien

In CHD:

Reduce risk of

death and non

fatal MI.

Active liver

disease or

unexplained

persistent

Constipat

ion

dyspepsi

a

Tablet

10

mg,20

mg, 30

Vidastat

40g I

tab NGT

Asses drug

expiration

date

>consider

135

cholester

ol in that

following

inhibition

of the

HWG-

COA

reductas

e

activity,

the LDL

receptor

activity

on the

liver is

increase

d and

this

leads to

increase

Reduce risk of

strike and

transient

ischemic

attacks. In

hypelipidemia:

an adjuct to

the diet to

reduce

elevated total-

c, LDL-C ,

apolipoprotien

B and TG in

patients with

primary hyper

choles

terolemia,

hanozygous

familial

hyrecholestero

elevations of

serum trans

aminoses

parphyria,

pregnancy

lactation

flatulence mg,40

mg

OD q8hr the 5 rights

of drug

administrati

on.

>obtain

baseline

data

>dissolve

solution

thoroughly

>

encourage

high fiber

diet, fluid.

> inform

patient

about the

mechanism

of drugs

>chart the

136

d

removal

of LDD

cholester

ol.

(KIMS.co

m)

gous or mixed

hyperlipidemia

.

(MIMS.co

procedure

>evaluate

effectivene

ss of drugs.

Drug Study

Generic

Name

Brand

Name

Classification Mechanis

m of

Action

Indication Contraindica

tion

Side

Effects

How

Supplied

Dosage/

Frequen

cy

Nursing

Interventio

n

Midozal

am

Dormic

um

Benzodiazepi

ness sedative

hyponotics

Inhibits

sympath

etic

Disturban

ces of

sleep

Premature

infants

myasthenia

Insomni

a in

psychosi

Ampule

5mg/1ml

5mg/

IVTT 2.8

mg OD

1. Assess

level of

sedation

137

nervous

system

activatio

n and

initiates

sedation

hyponoti

cs

rhythm,

insomnia

esp.difficu

lty in

falling

asllep

either

initially or

after

prematur

e

awakenin

g.

Sedation

in premed

before

surgical

or

diagnostic

procedure

gravis s severe

depressi

on

5ml,15

mg/3ml

Film

coated

tablet 15

mg

and level

of

consciousn

ess

through

out and for

2-6 hour

following

administrat

ion

2. Monitor

blood

pressure,

pulse and

respiration

continuous

ly during

administrat

ion

3.

138

s,

induction

and

maintena

nce of

anesthesi

a.

(MIMS.co

m)

Administer

IM doses

deep into

muscle

4. In form

the patient

that this

medication

will

decrease

mental

recall of

the

procedure

5. Instruct

patient to

inform

health care

profession

al prior to

139

administrat

ion if

pregnancy

is

suspected

Drug Study

Generic

Name

Brand

Name

Classificatio

n

Mechanism

of Action

Indicati

on

Contraindicati

on

Side

Effects

How

Suppli

ed

Dosage/

Frequen

cy

Nursing

Interventio

n

Ciprofloxa

cin

ciprob

ay

fluroquinolo

ne

Has a rigid

action in

the

For

acute

uncomp

Contraindicate

d to patients

having

Nausea,

diarrhea

,

Tablet

250

mg,

Ciproba

y 500 g

1 ½ tab

>asses

drug

expiration

140

ploriferatio

n phase of

a

bacterium,

a

segmental

twisting

and

untwisting

of

chromoso

mes take

place.

(MIMS.com

)

li-cated

urinary

tract

infectio

ns

hypersensitivit

y to

ciprofloxacin

or other

quilone

chemotherape

utic

vomiting

,

dyspepsi

a,

abdomin

al pain,

flatulenc

e,

dizzines

s

500

mg

Infusio

n 100

mg/30

ml

200

mg/20

ml

Film

coated

tablet

500

mg

PO bid date

>asses for

drug

tolerance

characteriz

ed

>obtain

baseline

v/s

>instruct

the

patients to

remain in a

stable

position for

2-3 hrs.

>advice

increase

fluid intake

>consider

141

patients

safety

>evaluate

effectivene

ss of drug

>chart

procedure

Drug Study

Generic

Name

Brand

Name

Classificati

on

Mechanism

of Action

Indication Contraindicat

ion

Side

Effects

How

Suppli

ed

Dosage/

Frequen

cy

Nursing

Interventio

n

rebamipi

de

Mucust

a

ANTACIDS Rebamipid

e is a

For acute

gastritis

Lactation. Rash,

pruritus,

Tablet

100

Mucosta

1 tab

1. Chedk

renal

142

mucosal

protective

agent and

is

postulated

to increase

gastric

blood flow,

prostaglan

din

biosynthes

is and

decrease

free

oxygen

radicals.

and

exacerbati

on of

chronic

gastritis,

gastric

ulcers

constipati

on,

diarrhoea,

nausea.

mg OD TID studies to

check

renal

function is

normal

2. Check

the pattern

of bowel

elimination

.

3. Record

the gastric

pain being

experience

d.

4. report

for coffee

ground

stools

143

5. if the

patient is

pregnant

has edema

or

hypertensi

ve, use low

sodium

antacids

Drug Study

Generic

Name

Bran

d

Nam

e

Classificati

on

Mechanism

of Action

Indicatio

n

Contraindica

tion

Side

Effects

How

Supplied

Dosage/

Frequen

cy

Nursing

Interventio

n

144

predniso

ne

pred corticoster

oids

The anti-

inflammato

ry effect is

due to

inhibition

of

prostaglan

din

synthesis,

the drug

also

inhibits

accumulati

on of

machropha

ges and

leukocytes

at sites of

inflammati

on and

Allergis

and

edemato

us

respirato

ry and

neoplast

ic

diseases

Gastric &

duodenal

ulcers,

systemic

fungal &

certain viral

infections,

glaucoma,

psychoses or

severe

psychoneuro

ses; live

vaccines;

hypersensitiv

ity to

glucocorticoi

ds.

Insomia,

nosia and

vomiting,

GI upset,

fatique,

dizziness,

muscle

weakness,

increased

hunger/thi

rst, joint

pain,

decreased

diabetic

control.

tablets:1

mg, 5mg,

10mg, 20

mg, 50

mg

Oral

solution:

5mg/5ml;

syrup

5mg/5ml;

20 mg 1

tab NGT

BID

1. note

reasons for

therapy,

type,

onset,

characteris

tics of

signs and

symptoms,

clinical

presentatio

n

2. monitor

CBC, ESR,

electrolyte

s, BP,

blood

sugar,

weights

and mental

145

inhibits

phagocytos

is and

lysosomal

enzyme

release.

status.

3. with

COPD

provide

rescue

doses and

instruct

client how

and when

to use.

4. with

chronic

pain,

titrate dose

to assess

for relief

146

Drug Study

Generic

Name

Brand

Name

Classificati

on

Mechanism

of Action

Indicati

on

Contraindica

tion

Side Effects How

Suppli

ed

Dosage/

Frequen

cy

Nursing

Intervention

Ivabradi

ne HCl

corala

n

Antiangina

Ivabradine

Ivabradine

is a pure

Chronic

angina

Resting

heart rate

Luminous

phenomena

film-

coated

5 mg 1

tab NGT

1. Assess

the client for

147

heart rate-

lowering

agent,

acting by

selective

and specific

inhibition of

the cardiac

pacemaker /

current that

controls the

spontaneou

s diastolic

depolarisati

on in the

sinus node

and

regulates

heart rate.

The cardiac

pectotis <60 bpm

prior to

treatment,

cardiogenic

shock, acute

MI, severe

hypotension

(<90/50

mmHg),

severe

hepatic

insufficiency,

sick sinus

syndrome,

SA block,

severe heart

failure,

pacemaker-

dependent

patient,

(phosphene

s), blurred

vision,

bradycardia

, 1st

degree AV

block,

ventricular

extrasystol

es,

headache,

dizziness.

tablet

5 mg,

7.5 mg

OD gastrointesti

nal

upset and

peripheral

edema.

2. Assess

pain and

limitation of

movement ;

note type,

location &

intensity

prior to & at

the peak

following

administrati

on.

3. Monitor

vital signs

148

effects are

specific to

the sinus

node with

no effect on

intra-atrial,

atrioventric

ular or

intraventric

ular

conduction

times, nor

on

myocardial

contractility

or

ventricular

repolarisati

on.

unstable

angina, 3rd

degree AV-

block.

Concomitant

potent

CYP3A4

inhibitors.

Pregnancy &

lactation.

and check

for

peripheral

edema.

d. Don’t

breastfeed

while taking

this drug.

4.

Discontinue

drug and

notify

physician if

signs and

symptoms of

hypersensiti

vity occur.

5. Caution

the patient

to avoid

149

concurrent

use of

alcohol with

this

medication.

Drug Study

Generic

Name

Brand

Name

Classificati

on

Mechanis

m of

Action

Indication Contraindicat

ion

Side

Effects

How

Supplie

d

Dosage/

Frequen

cy

Nursing

Interventi

on

Co

amoxicl

av

Agcom

en

Amoxicillin

and

enzyme

Prevents

the

plorefirati

Bacterial

infections

caused by

Pregnancy &

lactation.

Elderly &

Diarrhea,

hepatitis

&

tablet

625

625 mg

1 tab

NGT q 8

a. Assess

for allergy

to

150

inhibitor on of of

infecting

bacteria

by

inhibitng

synthesis

of

bacterial

capcule.

(mims.co

m)

amoxicillin-

resistant β-

lactamase

producing

strains.Thes

e include

actinomycos

is, biliary

tract

infections,

bronchitis,

endocarditis

,

gastroenteri

tis, typhoid

& para

typhoid

fever & UTI.

neonates.

Severe renal

impairment.

cholestati

c

jaundice.

Erythema

multiform

e,

Stevens-

Johnson

syndrom

e, toxic

epiderma

l

necrolysi

s &

exfoliativ

e

dermatiti

s.

mg hrs penicillin.

b. Instruct

to take

the entire

quantity

of drug

exactly as

prescribed

even after

she feels

better.

c.

Encourage

to

increase

fluid

intake.

d. Take

the

medicatio

151

n in full

stomach.

e. Report

for any

signs of

unusualiti

es.

( Wilson,

et. al,2004

page

1415).

Drug Study

Generic

Name

Brand

Name

Classificati

on

Mechani

sm of

Action

Indication Contraindica

tion

Side Effects How

Supplie

d

Dosage/

Frequen

cy

Nursing

Interventio

n

Ipratropi

um

Duave

nt

Antiasthm

atic

Stimulat

es beta

Manageme

nt of

Hypertrophi

c

Headache,p

ain,

Pulmon

eb

1 neb

now

1. Obtain

record and

152

salbutam

ol

sulfate,

2

receptor

s on the

bronchi.

Causes

less

tachycar

dia and

is longer

acting.

(Woods,

Sratto,

28)

reversible

bronchosp

asm

associated

w/

obstructive

airway

diseases

eg

bronchial

asthma,

COPD

obstructive

cardiomyop

athy or

tachyarryth

mia.

Hypersensiti

vity to soya

lecithin or

related food

products

(for MDI).

influenza,

chest pain;

nausea.

Bronchitis,

dyspnea,

coughing,

pneumonia,

bronchospa

sm,

pharyngitis,

sinusitis,

rhinitis.

solution

2.5 mL

baseline

vital sings

2. Assess

the

presence of

palpitations

and

dysrhythmi

as

3. Perform

assessmen

t of the

patient’s

mental

status

4. Warm

patient

about

possible

paradoxical

153

bronchospa

sm

5. use

cautiously

to patients

with CV

disorders,

hypertensi

on, renal

disease

and

diabetes.

154

IVF STUDY

Student’s Name: Group 4 Section R Date of Submission: January 8, 2009

Area: Chong Hua Hospital Cliinical Instructor: Benita Edelia D.

Agramon

Patient’s Name: Patient X Doctor: Dr. R. Go

Room/Bed No.: C-414 Date of Admission: December 13, 2008

Age: 66 years old Hospital No.: 0-800-22500-773

Status: Widowed Diet: Liquid diet

155

Type of

solutio

n

Classificatio

n

Content Mechanis

m of

action

Indications Contraindicatio

ns

How

supplie

d

Dosage Nursing

Responsibiliti

es

0.9%

Sodium

chlorid

e

solutio

n

Isotonic Each 1000

mL

contains

900mg of

Sodium

Chloride

Osmolarit

y:

308

mOsm/L

Electrolyte

s in 1000

mL:

Sodium…

Replaces

sodium

and

chloride

and

maintains

levels

(Lippincot

t Williams

& Wilkins:

2005,

879).

Fluid and

electrolyte

replacement

in

hyponatrem

ia caused by

electrolyte

loss or in

severe salt

depletion.

Contraindicate

d in patients

with conditions

in which

sodium

chloride

administration

is detrimental.

>contraindicat

ed in patients

with with

increased,

normal, or only

slightly

decreased

I.V. 1

liter

IVF

PNSS 1

liter @

30

gtts/mi

n

1. Monitor

electrolyte

levels

(Lippincott

Williams &

Wilkins: 2005,

879).

2. Explain use

and

Administratio

n of drug to

patient and

family

(Lippincott

Williams &

156

154 mmol

Chloride…

154 mmol

electrolyte

levels.

Wilkins: 2005,

879).

3.Tell Patient

to report

adverse

reactions

promptly

(Lippincott

Williams &

Wilkins: 2005,

879).

4.Regulate

flow rate as

ordered

(Lippincott

Williams &

Wilkins: 2005,

879).

6.Check on

skin integrity

157

for redness,

edema,

swelling and

pain

(Lippincott

Williams &

Wilkins: 2005,

879).

7.Do not let

the bottle be

consumed

totally to

prevent air

embolism

(Lippincott

Williams &

Wilkins: 2005,

879).

8.Check mfor

any bubbles

158

present on

the I.V. line

(Lippincott

Williams &

Wilkins: 2005,

879).

Type of

solution

Classification Content Mechanism of

action

Indications Contraindication

s

How

suppli

ed

Dosage Nursing

Responsibiliti

es

Dopami

ne

Sympathomim

etic, direct

acting and

indirect acting

Syntheti

c

Dopami

ne

Dopamine is

the

immediate

precursor of

epinephrine

in the body.

Adjunct to

standard

measures

to

improve:

BP,

Pheochromocyt

oma,

uncorrected

tachycardia,

ventricular

fibrillation, or

IVF

500 ml

PB

Dopami

ne IV @

30

gtts/min

1. Dilute just

prior to

administratio

n, solution

stable for 24

hr at room

159

Exogenously

administered,

it produces

direct

stimulation of

beta-1

receptors and

variable

(dose-

dependent)

stimulation of

alpha

receptors

(peripheral

vasoconstricti

on). Will

cause a

release of

norepinephrin

e from, as its

Cardiac

output,

urine

output, in

treatment

of shock,

unrespons

ive to fluid

replaceme

nt.

arrhythmias.

Pediatric clients.

temperature,

protect from

light.

2. To prevent

fluid

overload,

may use

more

concentrated

solutions with

higher doses.

3. Administer

using an

electronic

infusion

device.

Carefully

reconstitute

and calculate

160

storage sites.

These action

results in

increased

myocardial

contraction,

CO, and SV as

well as

increased

renal blood

flow and

sodium

excretion.

Exert little

effects on

DBP and

induces fewer

dosage.

4. When

discontinuing

, gradually

decrease

dose,

sudden

cessation

may cause

marked

hypotension.

5.Monitor VS,

I&O, and

ECG; titrate

infusion to

maintain SBP

as ordered.

6. Be

prepared to

monitor CVP

161

and PAWP.

Report

ectopy,

palpitations,

anginal pain,

or

vasoconstrict

ion.

7. Explain to

the family

that drug

administered

IV to improve

cardiac

function thus

increasing BP

and

improving

urine output.

162

8. Report any

chest pain,

increase

SOB,

headaches,

or IV site

pain.

Type of

solutio

n

Classificatio

n

Content Mechanism

of action

Indication

s

Contraindicatio

ns

How

supplie

d

Dosage Nursing

Responsibiliti

es

163

D5NSS Hypertonic Each 1000

mL

contains

1000mg

of Sodium

Chloride

Osmolarit

y:

500

mOsm/L

Electrolyte

s in 1000

mL:

Sodium…

354 mmol

Chloride…

354 mmol

The solution

has a higher

sodium

concentratio

n than to

the

intracellular

area thus by

virtue of

osmosis the

water is

taken out of

the cell the

cell shrinks.

This

increases

the plasma

volume of

the blood.

Rehydrat

e; has

free

water,

salt and

calories

Contraindicate

d in patients

with conditions

in which

sodium

chloride

administration

is detrimental.

>contraindicat

ed in patients

with with

increased,

normal, or only

slightly

decreased

electrolyte

levels.

I.V. 1

liter

IVF

D5NSS

1 liter

@ 30

gtts/mi

n

1. Monitor

electrolyte

levels

(Lippincott

Williams &

Wilkins: 2005,

879).

2. Explain use

and

Administratio

n of drug to

patient and

family

(Lippincott

Williams &

Wilkins: 2005,

879).

3.Tell Patient

to report

adverse

164

reactions

promptly

(Lippincott

Williams &

Wilkins: 2005,

879).

4.Regulate

flow rate as

ordered

(Lippincott

Williams &

Wilkins: 2005,

879).

6.Check on

skin integrity

for redness,

edema,

swelling and

pain

165

(Lippincott

166